Antiplatelet Therapy After Cardiac Arrest

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients. The reasons for this are probably slower gastrointestinal motility, absorption and liver metabolism required for clopidogrel to take action. Since ticagrelor has faster intestinal absorption and no need for liver metabolism we expect its effect to be good even in patients with therapeutic hypothermia after cardiac arrest. Patients treated with therapeutic hypothermia after cardiac arrest and percutaneous coronary intervention will be randomised into two groups. One will be treated with ASA and clopidogrel and the other with ASA and ticagrelor. Blood samples will be collected before and 2, 4, 12, 22 and 48 hours after P2Y12 inhibitor administration. Platelet function will be measured by VerifyNow P2Y12 assay and by Multiplate ADPTest. Differences between the groups will be analysed.

Hypothesis: Antiplatelet therapy with ticagrelor is more effective than therapy with clopidogrel in the comatose survivors of cardiac arrest treated with therapeutic hypothermia and percutaneous coronary intervention (PCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

NCT02469740

Myocardial Ischemia Coronary Artery Disease Endothelial Dysfunction

COMPLETED PHASE4

Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis

NCT01950416

ST Elevation Myocardial Infarction Fibrinolysis P2Y12 Inhibitor

COMPLETED PHASE4

the Effect Between Platelet Reactivation and Antiplatelet Drugs

NCT02198053

Drug Effect Disorder Platelet Procoagulant Activity Deficiency

UNKNOWN

Platelet Reactivity in Acute Non-disabling Cerebrovascular Events

NCT02506140

Stroke Ischemic Attack, Transient

COMPLETED PHASE2/PHASE3

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

NCT02330640

Antiplatelet Therapy of Coronary Artery Bypass

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrest Postresuscitation Syndrome Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clopidogrel

These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.

Group Type ACTIVE_COMPARATOR

Clopidogrel

Intervention Type DRUG

Ticagrelor

These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.

Group Type EXPERIMENTAL

Ticagrelor

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clopidogrel

Intervention Type DRUG

Ticagrelor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Clopidogrel (Plavix) Ticagrelor (Brilique)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female and male over 18 years old
* Unconscious survivors of cardiac arrest treated with therapeutic hypothermia
* Acute coronary syndrome (NSTEMI or STEMI) as a reason of cardiac arrest
* PCI with stent implantation
* Provision of informed consent prior to any study specific procedures is impossible because subjects are unconscious at the moment of inclusion

Exclusion Criteria

* Use of any P2Y12 inhibitors in last 10 days
* Use of prasugrel before and 48 hours after loading dose of P2Y12 inhibitor
* Use of eptifibatide before and 48 hours after loading dose of P2Y12 inhibitor
* Thrombocytopenia (\<50\*109/L)
* Allergic reaction to acetylsalicylic acid, clopidogrel or ticagrelor
* Ticagrelor contraindications: previous intracranial bleeding, active pathological bleeding, moderate to severe hepatic impairment, heart rate \< 40/min at presentation
* Suspected or confirmed pregnancy
* Use of bivalirudin before and 48 hours after loading dose of P2Y12 inhibitor

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No